Literature DB >> 25803136

Adjunctive Valproic Acid in Management-Refractory Hyperactive Delirium: A Case Series and Rationale.

Yelizaveta Sher1, Anne Catherine Miller1, Sermsak Lolak1, Andrea Ament1, José R Maldonado1.   

Abstract

Patients with delirium may fail to respond to standard therapies. Sixteen patients with management-refractory hyperactive delirium responded to adjunctive valproic acid, with complete resolution of hyperactive delirium in 13 cases. A rationale for using valproic acid in such circumstances is discussed.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25803136     DOI： 10.1176/appi.neuropsych.14080190

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN： 0895-0172            Impact factor:   2.198


  4 in total

Review 1.  Clinical Assessment and Management of Delirium in the Palliative Care Setting.

Authors:  Shirley Harvey Bush; Sallyanne Tierney; Peter Gerard Lawlor
Journal:  Drugs       Date:  2017-10       Impact factor: 9.546

2.  The COVID-19 conundrum: Where both the virus and treatment contribute to delirium.

Authors:  Brittany Woolley
Journal:  Geriatr Nurs       Date:  2021-04-27       Impact factor: 2.361

3.  Sodium Valproate versus Continuous Infusion of Haloperidol in Management of Agitated Critically Ill Patients.

Authors:  Ramadan Khalil; Mohamed Soliman; Mohamed Omer; Kamel Abdel Aziz; Khaled Hussein
Journal:  Open Access Maced J Med Sci       Date:  2019-08-13

Review 4.  Pathomechanisms of Non-Traumatic Acute Brain Injury in Critically Ill Patients.

Authors:  Wojciech Dabrowski; Dorota Siwicka-Gieroba; Malgorzata Gasinska-Blotniak; Sami Zaid; Maja Jezierska; Cezary Pakulski; Shawniqua Williams Roberson; Eugene Wesley Ely; Katarzyna Kotfis
Journal:  Medicina (Kaunas)       Date:  2020-09-13       Impact factor: 2.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.